Healthcare: Will Shire Be Bought Out? Plus, Alkermes Suffers a Setback
Industry Focus - Un pódcast de The Motley Fool
Categorías:
Takeda may buy Shire, but it might prove costly. Also, the FDA slaps Alkermes with a dreaded Refusal to File letter.
